Use of inhaled corticosteroids and the risk of non-fatal acute myocardial infarction

Journal of Hypertension

Volumn 26, Issue 1, 2008, Pages 124-129

  De Vries, Frank ^a   Pouwels, Sander ^a   Bracke, Madelon ^a,b   Lammers, Jan Willem ^b   Leufkens, Hubert ^a   Klungel, Olaf ^a   Van Staa, Tjeerd ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

C reactive protein; Confounding factors; Glucocorticoids; Inhaled corticosteroids; Myocardial infarction; Obstructive lung disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; XANTHINE DERIVATIVE;

ACUTE HEART INFARCTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG USE; FEMALE; HEART PROTECTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK REDUCTION;

EID: 37349076921     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f0ab4a     Document Type: Article

References (24)

1. Lanes SF, Garcia Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002; 57:683-686.
2. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
3. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
4. Pinto-Plata VM, Mullerova H, Toso JF, Fendjo-Tepie M, Soriano JB, Vessey RC, Celli BR. C-reactive protein in patients with COPD, control smokers and nonsmokers. Thorax 2006; 61:23-28.
5. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:760-765.
6. Sin DD, Man SF. Can inhaled steroids mend a broken heart in chronic obstructive pulmonary disease? Eur Respir J 2005; 25:589-590.
7. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60:992-997.
8. Ferguson GT, Calverly PMA, Anderson JA, Celli B, Jenkins C, Jones PW, et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) is well tolerated in patients with COPD over three years. Eur Respir J 2006; 28 (Suppl 50):34s.
9. Suissa S, Assimes T, Brassard P, Ernst P. Inhaled corticosteroid use in asthma and the prevention of myocardial infarction. Am J Med 2003; 115:377-381.
10. Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25:634-639.
11. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GDO, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25:1051-1056.
12. Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in the Netherlands (dissertation). The Netherlands: University of Utrecht; 1993.
13. Heerdink ER, Leufkens HG, Herings RMC, Ottervanger JP, Stricker BHC, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158:1108-1112.
14. De Vries F, Van Staa TP, Bracke MSGM, Cooper C, Leufkens HGM, Lammers JWJ. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005; 25:879-884.
15. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs 2002. Nydalen: Norwegian Institute of Public Health; 2002.
16. Schroeder EB, Welch VL, Couper D, Nieto FJ, Liao D, Rosamond WD, Heiss G. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2003; 158:1171-1181.
17. Anthonisen NR, Connett JE, Enright PL, Manfreda J, Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333-339.
18. Van Ganse E, Van der Linden PD, Leufkens HG, Herings RM, Vincken W, Ernst W. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J 1995; 8:1856-1860.
19. Aronow WS, Silent MI. Prevalence and prognosis in older patients diagnosed by routine electrocardiograms. Geriatrics 2003; 58:24-26; 36-38, 40.
20. Maitland-van der Zee AH, Klungel OH, Stricker BH, Van der Kuip DA, Hofman A, Leufkens HG, De Boer A. Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study. Pharm World Sci 2003; 25:70-72.
21. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59:574-580.
22. Takemura M, Matsumoto H, Niimi A, Ueda T, Matsuoka H, Yamaguchi M, et al. High sensitivity C-reactive protein in asthma. Eur Respir J 2006; 27:908-912.
23. Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan healthcare datafiles. Stat Med 1995; 14:2627-2643.
24. De Vries F, Pouwels S, Bracke M, Leufkens HGM, Cooper C, Lammers JWJ, Van Staa TP. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Safety 2007; 16:612-619.